Cleanascite™ Employed to Help Detect Tuberculosis Virulence Factors In Serum

MONMOUTH JUNCTION, NJ , June 24, 2022 -- Biotech Support Group reports on an article, describing the simplicity and efficiency of their lipid clearance sample preparation technology to improve a nanopore sensor peptide signature in order to identify and detect target peptides derived from two Mycobacterium tuberculosis (Mtb) virulence factors in serum. The citation is:

Zheng, Wenshu, et al. " Nanopore-based disease diagnosis using pathogen-derived tryptic peptides from serum ." Nano Today 45 (2022): 101515.

Recent studies indicate that current signatures produced by peptide-nanopore interactions can distinguish high purity peptide mixtures, but the utility of nanopore sensors in clinical applications still needs to be explored due to the inherent complexity of clinical specimens. For this, the study describes a methodology to select trypsin-digested peptide biomarkers suitable for use in an immunoprecipitation-coupled nanopore (IP-NP) assay, to produce a characteristic nanopore interaction signature. A technical hurtle was overcome as at first, Nanopore analysis of samples resulted in frequent and prolonged pore blockades and unstable current baselines. This appeared to result from lipid or lipoprotein complexes that were non-specifically adsorbed by the immunoprecipitation matrix. This was markedly reduced when samples were lipid extracted before immunoprecipitation.

Click to enlarge image


The article states “Treatment of digested serum samples with two commercial lipid removal agents revealed variable effectiveness in reducing these artifacts, with one reagent (LRA; synthetic calcium silicate hydrate) revealing little to no effect to reduce the frequency, duration, and extent of non-specific pore blockages…Serum digests treated with the second reagent (Cleanascite™) demonstrated the absence of these artifacts”. The article states “FP-10pep αHL signals detected from serum CFP10pep immunoprecipitates following effective lipid-depletion revealed blockade current and dwell time characteristics similar to those observed with syntheticCFP10pep standards or CFP10pep immunoprecipitates captured from PBS suspensions, and were not influenced by several factors responsible for clinical interferences.” The report concludes that the nanopore signal distinguished serum from a TB case, non-disease controls, and from a TB-case after extended anti-TB treatment, and believes this assay approach should be readily adaptable to other infectious and chronic diseases that can be diagnosed by peptide biomarkers.

“Lipids can often interfere with many analytical platforms for measuring proteins and peptides. I am very pleased to see that this article demonstrates the efficiency of Cleanascite™ over another common commercially available reagent. Now with this simple and fast sample prep step, better methods to diagnose infectious disease based on peptide biomarkers may be soon forthcoming” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

For Business Development , contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com